Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States

Background: Carfilzomib, an effective proteasome inhibitor agent for the therapy of relapsed and refractory multiple myeloma, has been related to a significant number of cardiovascular events. However, patterns of cardiovascular complications associated with this agent remain poorly characterized in...

Full description

Bibliographic Details
Main Authors: Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yang Cao, Zhen Lin, Xiang Zhou, Zhijian Guo, Jia He
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cardiovascular toxicity
carfilzomib
FAERS
disproportionality analysis
real-world evidence
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.735466/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2021.735466/full

Similar Items